The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
| العنوان: | The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia |
|---|---|
| المؤلفون: | Sang-Hyun Kim, Jun Kwan, Tae Ho Park, Shung Chull Chae, Kiyuk Chang, Taehoon Ahn, Chi Young Shim, Kook Jin Chun, Jae Kean Ryu, Tae Soo Kang, Doo Il Kim, Myung Ho Jeong, In Ho Chae, Seung Jae Joo, Young Won Yoon, Deuk Young Nah, Hong Seog Seo, Ki Chul Sung, Seok Yeon Kim, Jin Ok Jeong, Moo Yong Rhee, Seung-Jea Tahk, Dong Gu Shin, Wan Joo Shim, Hae Young Lee, Sung Yun Lee, Dong Joo Oh, Seung Woo Park, Tae Hyun Yang |
| المصدر: | BMC Pharmacology & Toxicology BMC PHARMACOLOGY & TOXICOLOGY(18) |
| بيانات النشر: | BioMed Central, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Hypercholesterolemia, Diastole, Tetrazoles, 02 engineering and technology, 030204 cardiovascular system & hematology, Pharmacology, Rosuvastatin, 03 medical and health sciences, Young Adult, 020210 optoelectronics & photonics, 0302 clinical medicine, Double-Blind Method, Internal medicine, 0202 electrical engineering, electronic engineering, information engineering, medicine, Humans, Pharmacology (medical), Fimasartan, In patient, Rosuvastatin Calcium, reproductive and urinary physiology, Hypertension, Aged, Life Change, business.industry, Incidence (epidemiology), Anticholesteremic Agents, Biphenyl Compounds, hemic and immune systems, Middle Aged, medicine.disease, biological factors, Pyrimidines, embryonic structures, Drug Therapy, Combination, Female, business, Angiotensin II Type 1 Receptor Blockers, Dyslipidemia, medicine.drug, Co administration, Research Article |
| الوصف: | Background Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events. The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and rosuvastatin in patients with hypertension and hypercholesterolemia. Methods We conducted a randomized double-blind and parallel-group trial. Patients who met eligible criteria after 4 weeks of therapeutic life change were randomly assigned to the following groups. 1) co-administration of fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV), 2) fimasartan 120 mg (FMS) alone 3) rosuvastatin 20 mg (RSV) alone. Drugs were administered once daily for 8 weeks. Results Of 140 randomized patients, 135 for whom efficacy data were available were analyzed. After 8 weeks of treatment, the FMS/RSV treatment group showed greater reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures than those in the group receiving RSV alone (both p |
| اللغة: | English |
| تدمد: | 2050-6511 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa94070a395ae8304c7b03de2320564eTest http://europepmc.org/articles/PMC5217661Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....aa94070a395ae8304c7b03de2320564e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20506511 |
|---|